PCI will showcase its significant serialisation expertise and EU presence at the event, highlighting the organisation’s ongoing programme of investment and expansion to triple its market-leading serialisation capacity in Europe, alongside North America.
PCI has been serialising commercial drug product for more than six years, significantly expanding its global capacity well in advance of meeting the implementation deadlines for the European Falsified Medicines Directive (EU FMD).
Building on the organisation’s existing serialisation experience, the programme has entailed a series of technological and facility developments at its sites in Europe and North America to benefit its global supply network.
Visitors at Pharmapack 2018 have the chance to find out more about PCI’s serialisation specialism and how its enhanced capabilities can support their own preparations to comply with the new regulations.
Gareth Lewis, Commercial and Supply Chain Director at PCI Pharma Services, said: “Pharmapack is a great opportunity for us to share our increasing serialisation expertise and meet visitors who are keen to understand more about how our experience can help them in this important area. We will be at our stand ready to answer any questions, update people on the latest developments and support attendees with their packaging needs and serialisation challenges.”
As well as serialisation, PCI has been actively investing in its core business and key site expansion in cold chain infrastructure and capacity.
PCI has expanded its EU footprint with its most recent acquisition in Ireland and site expansions at its Tredegar and Bridgend facilities in the UK, helping provide a supply solution to support pharmaceutical and biotech companies looking to address potential concerns regarding Brexit uncertainty.
